Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adolescents

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04951388
Recruitment Status : Recruiting
First Posted : July 6, 2021
Last Update Posted : October 6, 2021
Sponsor:
Information provided by (Responsible Party):
Medigen Vaccine Biologics Corp.

Brief Summary:
The purpose of this study is to assess the safety and immunogenicity of MVC-COV1901 vaccine compared to placebo in participants aged ≥ 12 to < 18 years.

Condition or disease Intervention/treatment Phase
Covid19 Vaccine Biological: MVC-COV1901(S protein with adjuvant) Biological: MVC-COV1901(Saline) Phase 2

Detailed Description:
This is a Phase II, prospective, placebo-controlled, double-blinded (investigator/site staff and participants), multi-center study; the Sponsor will be blinded until the interim analysis. Participants aged ≥ 12 to < 18 years will be enrolled. All eligible participants will be randomized to receive either MVC-COV1901 or placebo in a 6:1 ratio.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 385 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
Official Title: A Phase II, Prospective, Double-blinded, Multi-Center Study to Evaluate the Safety, Tolerability, and Immunogenicity of the SARS CoV 2 Vaccine Candidate MVC COV1901 in Adolescents
Actual Study Start Date : July 22, 2021
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : May 2022

Arm Intervention/treatment
Experimental: MVC-COV1901(S protein with adjuvant)
S-2P protein with CpG and Aluminum Hydroxide/0.5mL
Biological: MVC-COV1901(S protein with adjuvant)
Approximately 330 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) and Visit 4 (Day 29) via intramuscular (IM) injection in the deltoid region

Placebo Comparator: MVC-COV1901(Saline)
Saline/0.5 mL
Biological: MVC-COV1901(Saline)
Approximately 55 participants will receive 2 doses of MVC-COV1901(Saline) at Visit 2 (Day 1) and Visit 4 (Day 29) via IM injection in the deltoid region




Primary Outcome Measures :
  1. Incidence of Adverse Events(AEs) [Safety and Tolerability] [ Time Frame: Day 1 to 28 days after the second vaccination ]

    To evaluate the incidence of Adverse Events(AEs) of MVC-COV1901 from Visit 2 (Day 1) to Visit 6 (28 days after the second dose of study intervention) in terms of the number and percentage of participants with the occurrence of:

    Solicited local AEs (up to 7 days after each dose of study intervention) Solicited systemic AEs (up to 7 days after each dose of study intervention) Unsolicited AEs (up to 28 days after each dose of study intervention) AE of Special Interest (AESI) Vaccine-Associated Enhanced Disease(VAED) Serious adverse events (SAEs)


  2. Immunogenicity of MVC-COV1901-1 [ Time Frame: Day 1 to 28 days after the second vaccination ]

    To evaluate the immunogenicity of MVC-COV1901, as compared to placebo, in terms of neutralizing antibody titers.

    The neutralizing antibody titers at Visit 6 (28 days after the second dose of study intervention) in terms of:

    -Geometric mean titers (GMT)


  3. Immunogenicity of MVC-COV1901-2 [ Time Frame: Day 1 to 28 days after the second vaccination ]

    To evaluate the immunogenicity of MVC-COV1901, as compared to placebo, in terms of neutralizing antibody titers.

    The neutralizing antibody titers at Visit 6 (28 days after the second dose of study intervention) in terms of:

    -Seroconversion rate (SCR)


  4. Immunogenicity of MVC-COV1901-3 [ Time Frame: Day 1 to 28 days after the second vaccination ]

    To evaluate the immunogenicity of MVC-COV1901, as compared to placebo, in terms of neutralizing antibody titers.

    The neutralizing antibody titers at Visit 6 (28 days after the second dose of study intervention) in terms of:

    -GMT ratio



Secondary Outcome Measures :
  1. Incidence of Adverse Events(AEs) [Safety and Tolerability] [ Time Frame: Day 1 to 180 days after the second vaccination ]

    To evaluate the Incidence of Adverse Events(AEs) of MVC-COV1901 over the study period in terms of the number and percentage of participants with the occurrence of:

    >= Grade 3 AE AE of Special Interest (AESI) Vaccine-Associated Enhanced Disease(VAED) Serious adverse events (SAEs)


  2. Immunogenicity of MVC-COV1901-1 [ Time Frame: Day 1 to 180 days after the second vaccination ]

    To evaluate the immunogenicity of MVC-COV1901, as compared to placebo, in terms of antigen-specific immunoglobulin titers and neutralizing antibody titers.

    The antigen-specific immunoglobulin titers and neutralizing antibody titers at Visit 4 (28 days after the first dose of study intervention), Visit 6 (28 days after the second dose of study intervention), Visit 8 (90 days after the second dose of study intervention) and Visit 9 (180 days after the second dose of study intervention) in terms of:

    -GMT


  3. Immunogenicity of MVC-COV1901-2 [ Time Frame: Day 1 to 180 days after the second vaccination ]

    To evaluate the immunogenicity of MVC-COV1901, as compared to placebo, in terms of antigen-specific immunoglobulin titers and neutralizing antibody titers.

    The antigen-specific immunoglobulin titers and neutralizing antibody titers at Visit 4 (28 days after the first dose of study intervention), Visit 6 (28 days after the second dose of study intervention), Visit 8 (90 days after the second dose of study intervention) and Visit 9 (180 days after the second dose of study intervention) in terms of:

    -SCR


  4. Immunogenicity of MVC-COV1901-3 [ Time Frame: Day 1 to 180 days after the second vaccination ]

    To evaluate the immunogenicity of MVC-COV1901, as compared to placebo, in terms of antigen-specific immunoglobulin titers and neutralizing antibody titers.

    The antigen-specific immunoglobulin titers and neutralizing antibody titers at Visit 4 (28 days after the first dose of study intervention), Visit 6 (28 days after the second dose of study intervention), Visit 8 (90 days after the second dose of study intervention) and Visit 9 (180 days after the second dose of study intervention) in terms of:

    -GMT ratio




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male or female participant ≥ 12 to < 18 years of age at randomization.
  • Body mass index (BMI) at or above the third percentile according to World Health Organization (WHO) BMI-for-age at the Screening Visit.
  • Female participant must:

    1. Be either of non-childbearing potential, i.e. surgically sterilized (defined as having undergone hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy; tubal ligation alone is not considered sufficient);
    2. Or, if of childbearing potential, be abstinent or agree to use medically effective contraception from 14 days before screening to 30 days following the last injection of study intervention. Acceptable forms include:

    i. Implanted hormonal methods of contraception or placement of an intrauterine device or intrauterine system ii. Established use of hormonal methods (injectable, pill, patch or ring) combined with barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository

  • Has a negative pregnancy test
  • Participant is willing and able to comply with all required study visits and follow-up required by this protocol.
  • Participant has not travelled overseas within 14 days of screening and will not have any oversea traveling throughout the study period.
  • Participant and the participant's legal representative must understand the procedures of the study and provide written informed consent.

Exclusion Criteria:

  • Pregnant or breast feeding or have plan to become pregnant in 30 days after last administration of study intervention.
  • Currently receiving or received any investigational intervention within 30 days prior to the first dose of study intervention.
  • Participant previously received a coronavirus vaccine.
  • Administered any licensed live-attenuated vaccines within 28 days or other licensed non-live-attenuated vaccines within 7 days prior to the first dose of study intervention.
  • Administered any blood product or intravenous immunoglobulin administration within 12 weeks prior to the first dose of study intervention.
  • Currently receiving or anticipate to receive concomitant immunosuppressive or immune-modifying therapy (excluding inhaled, topical skin and/or eye drop-containing corticosteroids, low-dose methotrexate, or < 2 weeks of daily receipt of prednisone less than 20 mg or equivalent) within 12 weeks prior to the first dose of study intervention.
  • Currently receiving or anticipate to receive treatment with tumor necrosis factor (TNF)-α inhibitors, e.g. infliximab, adalimumab, etanercept within 12 weeks prior to the first dose of study intervention.
  • Major surgery or any radiation therapy within 12 weeks prior to the first dose of study intervention
  • Immunosuppressive illness or immunodeficient state, including hematologic malignancy, history of solid organ, bone marrow transplantation, or asplenia.
  • Personal or family (linear or collateral relatives by blood within two generations) history of Guillain-Barré syndrome.
  • A history of malignancy with potential risk for recurrence after curative treatment, or current diagnosis of or treatment for cancer (exceptions are squamous and basal cell carcinomas of the skin and treated uterine cervical carcinoma in situ, at the discretion of the investigator).
  • Bleeding disorder considered a contraindication to intramuscular injection or phlebotomy.
  • Participant with ongoing acute diseases or serious medical conditions which will interfere with adherence to study requirements, or the evaluation of any study endpoint. Acute diseases or serious medical conditions include cardiovascular, pulmonary, hepatic, neurologic, metabolic, renal, psychiatric condition (e.g. alcoholism, drug abuse, anorexia or severe depression), current severe infections, autoimmune disease, medical history, physical findings, or laboratory abnormality that in the investigators' opinion are not in stable condition and participating in the study could adversely affect the safety of the participant.
  • Participant with previous known SARS-CoV-1 or 2 infection.
  • Participant with a history of hypersensitivity to any vaccine or a history of allergic disease or reactions likely to be exacerbated by any component of the MVC-COV1901.
  • Body (oral, rectal, or ear) temperature ≥ 38.0°C or acute illness (not including minor illnesses such as diarrhea or mild upper respiratory tract infection at the discretion of the investigator) within 2 days before the first dose of study intervention.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04951388


Contacts
Layout table for location contacts
Contact: Tim Huang +886277450830 ext 605 ChunHao@medigenvac.com
Contact: Howard Cheng +886277450830 ext 601 Howardcheng@medigenvac.com

Locations
Layout table for location information
Taiwan
Mackay Memorial Hospital Hsinchu Not yet recruiting
Hsinchu, Taiwan
Contact: Chien-Yu Lin, M.D.       6159@mmh.org.tw   
Chang-Guang Memorial Hospital Lin-Kou Recruiting
Taipei, Taiwan
Contact: Cheng-Hsun Chiu, M.D., Ph.D.       chchiu@adm.cgmh.org.tw   
Principal Investigator: Cheng-Hsun Chiu, M.D., Ph.D.         
MacKay Memorial Hospital Not yet recruiting
Taipei, Taiwan
Contact: Nan-Chang Chiu, M.D.       ncc88@ms2.mmh.org.tw   
Principal Investigator: Nan-Chang Chiu, M.D.         
National Taiwan University Hospital-HsinChu Recruiting
Taipei, Taiwan
Contact: Boon-Fatt Tan, M.D.       wenfa80@gmail.com   
National Taiwan University Hosptial Recruiting
Taipei, Taiwan
Contact: Li-Min Huang       lmhuang@ntu.edu.tw   
Principal Investigator: Li-Min Huang, M.D., Ph.D.         
Sponsors and Collaborators
Medigen Vaccine Biologics Corp.
Investigators
Layout table for investigator information
Principal Investigator: Li-Min Huang, M.D., Ph.D. National Taiwan University Hospital
Layout table for additonal information
Responsible Party: Medigen Vaccine Biologics Corp.
ClinicalTrials.gov Identifier: NCT04951388    
Other Study ID Numbers: CT-COV-22
First Posted: July 6, 2021    Key Record Dates
Last Update Posted: October 6, 2021
Last Verified: August 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Medigen Vaccine Biologics Corp.:
Covid19 Vaccine
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Somatomedin B
Trypsin Inhibitors
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action